Physician profile
Matthew S Devane
NPI 1770511040
$6,681.88
in general payments reported to CMS, 2019-2025
33 companies · $2,718 in 2025
The $2,718 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $104 · 2021: $97.01 · 2023: $2,010 · 2024: $1,753 · 2025: $2,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,332 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,331.87 |
| Education | $149.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $869.95 | 2023-2025 | |
| Aop Health US, LLC | $812.06 | 2025 | Rapiblyk |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $552.65 | 2021-2025 | Lifevest |
| Biotronik INC. | $470.76 | 2023-2025 | Amvia Edge, Acticor 7 Vr-T Dx, Renamic Neo |
| Novo Nordisk INC | $459.28 | 2023-2025 | Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $402.23 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $300.53 | 2023-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $294.91 | 2023-2025 | Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd, Accolade Sr |
| Bayer Healthcare Pharmaceuticals INC. | $266.37 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $260.49 | 2023-2025 | Jardiance |
| Esperion Therapeutics, INC. | $232.80 | 2023-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $195.32 | 2023-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $194.04 | 2023-2025 | Wainua, Farxiga |
| Philips North America LLC | $186.63 | 2024-2025 | (5050) Ext Holter, Mcot |
| Abbott Laboratories | $174.46 | 2020-2025 | Gallant, Cardiomems |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $141.52 | 2023-2025 | Verquvo, Winrevair |
| Cvrx, INC. | $130.78 | 2025 | Barostim Neo System |
| Heartflow, INC. | $117.34 | 2024-2025 | |
| Bridgebio Pharma, INC. | $96.39 | 2025 | Attruby |
| Pfizer INC. | $89.25 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $80.48 | 2023-2024 | |
| Atricure, INC. | $71.96 | 2024-2025 | Atriclip Laa Exclusion System, Epi-Sense Guided Coagulation System With Visitrax |
| Edwards Lifesciences Corporation | $67.86 | 2023-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Kiniksa Pharmaceuticals International, Plc | $47.20 | 2024 | Arcalyst |
| Impulse Dynamics (USA) INC. | $24.84 | 2023 | Optimizer |
| Scpharmaceuticals INC. | $24.04 | 2024 | |
| Cordis US Corp. | $20.40 | 2025 | Mynx Control Venous |
| Actelion Pharmaceuticals US, INC. | $19.59 | 2023 | Opsumit, Uptravi |
| Kiniksa Pharmaceuticals, Ltd. | $17.79 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $17.72 | 2023 | Inspire |
| Kestra Medical Technology Services, INC. | $14.21 | 2024 | Assure Wcd |
| Abiomed | $14.13 | 2024 | Impella |
| Alnylam Pharmaceuticals INC. | $13.90 | 2025 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Devane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.